Learning Hub

< BACK Advancing Psoriatic Arthritis: Rheumatologist Ilja Tchetverikov's Insights on iPROLEPSIS May 22, 2024 Exploring Innovative Approaches to Disease Management and Patient Care in Psoriatic Arthritis" Ilja Tchetverikov , a rheumatologist and project partner from the CICERO Foundation (the Netherlands), provides insights into the iPROLEPSIS project's endeavours. He emphasises the need for a deeper understanding of psoriatic arthritis , a chronic inflammatory condition impacting various body parts due to immune system disturbances. I. Tchetverikov highlights the project's focus on investigating disease progression factors and developing non-invasive measurement tools . “Everybody can measure anything, but then you have to know what you're measuring. The whole idea of the project is that we combine two strengths. One of them is providing and developing a technical solution on how to measure the disease activity. And from the other side, we are going to label the data coming in from the system, from the clinical point of view. So we will be able to say whether or not some people have a low or high level of disease activity. So it's one part of the investigation. The other part of the investigation is to see whether other factors, which are already known to influence the whole system of your human body, like stress factors and some, for instance, gut microbiome composition, can also change during the course of the disease and how they are influencing the course of the disease itself,” states Ilja Tchetverikov . Through a collaborative effort integrating clinical expertise and technical innovation, the project aims to assess disease activity levels and explore external factors accurately. iPROLEPSIS interview.png iPROLEPSIS interview.png 1/1 PREVIOUS NEXT

< BACK Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs Feb 5, 2026 New iPROLEPSIS publication presents a smartphone-based approach for remote joint swelling assessment in psoriatic arthritis A new publication from the iPROLEPSIS project has been published in the proceedings of the 2025 IEEE International Conference on E-health Networking, Application & Services (HealthCom) . The study investigates the use of smartphone photographs to support the remote assessment of swollen joints in patients with inflammatory arthritis, focusing on psoriatic arthritis. The proposed method classifies each interphalangeal joint in hand photographs as swollen or not swollen, supporting scalable and patient-friendly monitoring approaches. Read the full publication: https://zenodo.org/records/18481583 iPROLEPSIS_Apostolidis G._HealthCom.png iPROLEPSIS_Apostolidis G._HealthCom.png 1/1 PREVIOUS NEXT

< BACK Initiation of the iPROLEPSIS-PDPID Study Oct 22, 2024 Initiating Patient Enrollment for Psoriatic Arthritis Research The PsA digital phenotyping and inflammation drivers study (iPROLEPSIS-PDPID) has officially been initiated. The first patient was enrolled in the Netherlands in early September. The iPROLEPSIS-PDPID study focuses on using smart devices and clinical data to develop AI-driven models for personalised monitoring and flare prediction. This approach aims to empower patients by providing tools to better understand their condition. The study seeks to develop unobtrusive and affordable digital biomarkers capable of detecting changes in disease activity, including flares, and identifying their triggers in patients with psoriatic arthritis (PsA). The study is being conducted in four countries: the Netherlands, the UK, Portugal, and Greece. Patient recruitment is planned to start in the UK by the end of October, with recruitment in Greece and Portugal expected later this year. The miPROLEPSIS phone app is used in this study. The app is installed on patients' smartphones and acts as a data collection tool, which will be used to develop and train algorithms. The app measures physical activity, sleep duration, self-registered flares, and daily records of pain, fatigue, sleep quality, and morning stiffness. Additionally, the Garmin Vivoactive 5 smartwatch is used to collect data on physical activity, heart rate, heart rate variability, and sleep quality. 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 6 Oct 9, 2024 Latest News from iPROLEPSIS Welcome to the 6th edition of the iPROLEPSIS newsletter. In this edition, we share the latest updates and progress from our project, including new developments, recent publications, and reflections on key events. iPROLEPSIS project newsletter_October 2024_ Issue No. 6 .pdf Download PDF • 4.41MB 1/1 PREVIOUS NEXT

< BACK AINIGMA Technologies at InnoHealth Forum 2024 Sep 24, 2024 Highlights from InnoHealth Forum 2024 iPROLEPSIS colleagues from the AINIGMA Technologies team participated in the InnoHealth Forum 2024 (20-21 September, 2024), an event that promotes and highlights innovative health technology solutions for the benefit of humanity. With 25 exhibitors, 50+ live demos of cutting-edge health products and services and over 130 matchmaking meeting and networking opportunities, this forum was a great opportunity to spread the word about the iPROLEPSIS project and connect with potential end-users. 1/5 PREVIOUS NEXT

< BACK State-of-the-art analysis and datasets landscape Nov 6, 2023 Initial review, focusing on the state-of-the-art literature and existing datasets in the field of PsA Psoriatic arthritis is a chronic immune-mediated inflammatory arthritis occurring in patients with PsO. The disease manifestation can be heterogeneous between subjects, and the resulting musculoskeletal impairment can interfere with physical function as well as the quality of life of patients. In a collaborative effort, the iPROLEPSIS partners completed an initial extensive review, focusing on the state-of-the-art literature and existing datasets in the field of PsA, with a special focus on flare dynamics. The primary goal was to enhance the understanding of PsA by investigating disease symptoms, factors associated with flares, and markers for disease development and monitoring. The insights gained from the literature will provide background for various aspects of iPROLEPSIS research, such as investigating PsA inflammation drivers and monitoring, developing the iPROLEPSIS digital health ecosystem for personalised preventive care, and conducting clinical studies. Moreover, various multi-source datasets have been identified that can potentially yield valuable information for the discovery of PsA inflammation drivers and the development of novel digital biomarkers and predictive models for disease monitoring and progression prognosis. The identified datasets will be assessed for relevancy and usability, retrieved, harmonised and curated. These datasets and predictive models will contribute to the research on PsA monitoring and inflammation drivers. In addition, the identified existing datasets will also guide the development of the Lifestyle AI-driven recommendation system and the Serious Games. The key takeaways are: Fatigue, pain and stiffness are commonly reported symptoms in PsA Flare may be triggered by alterations in mood, stress, sleep, bowel movements, and environmental factors Flare may affect mood, stress, sleep, bowel movements, physical activity and fine motor skills Certain symptoms of PsA may also trigger or be triggered by flare Clinical measurements of PsA symptoms and hypothesized flare associated factors, mainly include questionnaires The use of smartphone and wearables to monitor physical activity (mainly through accelerometer data), fine motor skills (through keystroke dynamics), heart rate, heart rate variability have also shown potential to measure PsA symptoms and hypothesized flare associated factors Electrography techniques can also be used in the assessment of certain symptoms and flare associated factors Genetic factors may contribute to development of PsA, pain perception and response to treatment. Gut microbiome may be involved in PsA. MCs in skin are suggested to play a role in skin inflammation Monitoring of PsA can be achieved through clinical examination for inflamed joints, enthesitis dactylitis, nail and skin and subsequent calculation of relative indices and composite scores Imaging-based approaches including images obtained from smartphones and optoacoustics represent a complementary or alternative approach to clinical assessment Data-driven models can serve to find predictive relations even when the underlying mechanisms are poorly understood or are too complex. Recommendations and SGs present a potential approach to modify and improve diet and physical activity Besides diet and physical activity, SGs can also address other aspects of disease, including medication adherence, social support, cognition, breathing, biological and neural function OMOP CDM was opted to be used for standardising the datasets Future steps include an update on state-of-the-art literature and measurement tools on the topics covered by initial research and the identification of new datasets that could be relevant for data-driven models. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Highlights from IFPA 2024 Jun 28, 2024 iPROLEPSIS at IFPA 2024 The 7th World Psoriasis & Psoriatic Arthritis Conference, held on June 27-29, 2024, brought together leading experts and researchers to discuss the latest advancements in psoriasis and psoriatic arthritis. Dr Laura Coates from the University of Oxford discussed the potential to prevent psoriatic arthritis, including the work being done in iPROLEPSIS and HIPPOCRATES IMI. 1/6 PREVIOUS NEXT

< BACK iPROLEPSIS at IEEE HealthCom 2025: AI-Enabled Digital Health for Psoriatic Arthritis Nov 3, 2025 Project researchers presented new studies, co-chaired a workshop, and joined a panel on digital innovation in healthcare in Abu Dhabi The iPROLEPSIS team participated in the IEEE HealthCom 2025 Conference , held 21–23 October 2025 and hosted by Khalifa University in Abu Dhabi, United Arab Emirates . The event gathered international experts in digital health , artificial intelligence , and biomedical technologies to discuss how AI can improve the understanding and management of non-communicable diseases . Modeling joint swelling through smartphone photographs Giorgos Apostolidis from the Signal Processing & Biomedical Technology Unit – AUTH presented the paper “Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs”. By analyzing smartphone photos of hands, the study showcased that a digital estimation of joint thickness, namely effective width , with the aid of a logistic regression model , can serve as an effective tool for detecting interphalangeal joint swelling in people with PsA .This approach was validated on a real-world dataset collected within the PDPID study . Giorgos Apostolidis (Signal Processing & Biomedical Technology Unit – AUTH) Designing exergames for Psoriatic Arthritis care Prof. Leontios Hadjileontiadis (AUTH) presented the paper “Designing Exergames for Psoriatic Arthritis: The Spy and Zen Forest Paradigms”. The Spy and Zen Forest exergames were co-designed to complement PsA care by making therapeutic exercises more engaging and accessible at home. Using real-time body tracking on mobile devices , these games promote dynamic movement to enhance mobility and strength, and calm stretching for flexibility and relaxation. Prof. Leontios Hadjileontiadis (Signal Processing & Biomedical Technology Unit-AUTH) Panel discussion: Digital Bridges for Better Health Project Coordinator Prof. Leontios Hadjileontiadis , Scientific & Technical Manager Vasileios Charisis , and Stelios Hadjidimitriou from the Signal Processing & Biomedical Technology Unit – AUTH , together with Dr. Kosmas Dimitropoulos from the Centre for Research & Technology Hellas (CERTH) and Prof. Mohamed Seghier from Khalifa University , participated in the panel discussion “Digital Bridges for Better Health: AI Innovation from Europe to the Middle East and North Africa (MENA),” moderated by Giorgos Apostolidis. The panel provided insights into: The technical challenges in integrating AI with existing healthcare IT systems, How key stakeholders can collaborate to ensure AI digital health tools are user-friendly and clinically relevant, The role of patient engagement and digital literacy in the effectiveness of AI tools in chronic disease management How socio-cultural differences between Europe and MENA can influence the design and adoption of AI digital health solutions What are the key regulatory challenges in Europe and MENA regarding the use of AI in healthcare and what joint efforts can be undertaken to harmonize standards in these regions During the session, the iPROLEPSIS project and its AI-enabled digital health tools for assisting Psoriatic Arthritis management and care were highlighted as a case study of AI solutions with potential to improve outcomes for people with non-communicable diseases . Panel discussion "Digital Bridges for better health: AI Innovation from Europe to the Middle East and North Africa (MENA)" Workshop chairing Scientific & Technical Manager Vasileios Charisis from the Signal Processing & Biomedical Technology Unit-AUTH co-chaired the workshop "AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact" . The workshop was co-organised with the AI-PROGNOSIS Horizon Europe project and included research works in the fields of psoriatic arthritis, Parkinson's disease, multiple sclerosis and post-stroke rehabilitation. Two of the presented papers stem from research carried out within iPROLEPSIS: Apostolidis et al., Modeling Interphalangeal Joints for Swelling Assessment in Psoriatic Arthritis via Smartphone Photographs Ramalho et al., Designing exergames for psoriatic arthritis: The Spy and Zen Forest paradigms Workshop “AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact” The iPROLEPSIS and AI-PROGNOSIS teams from AUTH participated jointly at IEEE HealthCom 2025 , highlighting their shared commitment to advancing AI-enabled digital health solutions that enhance the understanding, early detection, and management of chronic diseases . iPROLEPSIS and AI-PROGNOSIS team members PXL_20251021_131742947.MP.jpg 2.jpg IMG_2954.jpg PXL_20251021_131742947.MP.jpg 1/11 PREVIOUS NEXT

< BACK Psoriatic Arthritis Awareness Day 2024 Sep 27, 2024 Advancing Psoriatic Arthritis Care with Technology and Research On 28 September, we celebrate Psoriatic Arthritis Awareness Day, a day dedicated to raising awareness about this condition and its impact on patients' lives. The iPROLEPSIS project is dedicated to improving our understanding and management of psoriatic arthritis. Did you know that psoriatic arthritis affects 112 out of 100,000 adults worldwide? This condition causes inflammation, pain, and fatigue, significantly affecting daily life. Therefore, finding better ways to monitor and manage it is important. PROLEPSIS-PDPID Study The iPROLEPSIS-PDPID study focuses on using smart devices and clinical data to develop new AI-driven models for personalised monitoring and flare prediction. This innovative approach seeks to empower patients by providing them with the tools they need to understand their condition better. miPROLEPSIS App A digital tool designed to help patients in tracking their condition. By collecting data from smartphones and smartwatches, the app offers insights into disease triggers and prognosis. This personalised information can help patients manage their symptoms more effectively, leading to improved health outcomes. Collaborative Efforts Conducted across four countries - the Netherlands, UK, Portugal, and Greece - the iPROLEPSIS project brings together experts and patients to transform the care of psoriatic arthritis. Through collaboration, the project aims to develop innovative solutions that cater to the needs of patients, enhancing their quality of life. Join Us in Raising Awareness As we celebrate Psoriatic Arthritis Awareness Day, we invite you to join us in promoting better management and understanding of psoriatic arthritis. Together we can make a difference in the lives of those living with this condition. 1/1 PREVIOUS NEXT

< BACK The protocol for iPROLEPSIS-PDPID study approved in the Netherlands Nov 12, 2023 Ongoing preparation for iPROLEPSIS-PDPID study initiation In November 2023, the protocol for the PsA Digital Phenotyping and Inflammation Drivers Study (iPROLEPSIS-PDPID) received ethical approval In the Netherlands. Approvals in the UK, PT and GR are in progress. The research will be conducted in the Netherlands, the UK, Portugal and Greece. The primary objective of the iPROLEPSIS-PDPID is to establish a development cohort to create smartphone and smartwatch-based, AI-driven digital biomarkers for the remote assessment and monitoring of individuals with psoriatic arthritis. Two action types will occur in the development cohort: measure and predict. Measure: To develop novel smartphone and smart device digital biomarkers for the assessment of inflammatory symptoms with a particular focus on the recognition of changes in movement patterns, pain, fatigue, and morning stiffness in comparison to the gold standard – medical evaluation by clinical evaluation of the joints, tendons and skin. Predict: To predict the change from uninflamed to inflamed using three triggers that may cause longstanding inflammation in psoriatic arthritis patients at risk for flare. Those three triggers are stress, mechanical stress and changes in the gut microbiome. To achieve these objectives, iPROLEPSIS-PDPID will leverage cutting-edge technology and a comprehensive set of products, such as a mobile phone app and a smartwatch. The miPROLEPSIS phone app, which will be used in this study, is currently under development. The app will be installed on the patients’ smartphones and utilised as a data collector before being used to develop and train algorithms. mIPROLEPSIS app.png mIPROLEPSIS app.png 1/1 PREVIOUS NEXT

< BACK Workshop at PETRA 2024: Advancing Personalised Health Through Multimodal Sensing and Innovative Environments Jan 25, 2024 Exploring the Future of Healthcare: AI-PROGNOSIS and iPROLEPSIS Projects Collaborate for Workshop on Human Health, Habits, and Behavior The workshop "AGENT - MultimodAl SiGnal Sensing/Analysis, Innovative Interactive Environments, and PersoNalized Behavioral Modeling for Improving QualiTy-of-Life" has been accepted in PETRA 2024! The workshop will be organised by the Centre for Research & Technology Hellas , Aristotle University of Thessaloniki , and Faculdade de Motricidade Humana in cooperation with the AI-PROGNOSIS and iPROLEPSIS projects. More info about the workshop: http://www.petrae.org/workshops/AGENT.html AI-PROGNOSIS is a Horizon Europe-funded project developing Artificial intelligence-based solutions for #Parkinson 's disease risk assessment and prognosis. iPROLEPSIS is a Horizon Europe-funded project developing a novel personalised digital care ecosystem for people with #Psoriatic #arthritis . The workshop aims to attract an interdisciplinary group of researchers involved in research related to early detection, assessment and monitoring of human health, habits and behaviour. The workshop will focus on novel technologies applied in real or virtual environments and aim to enhance the quality of daily living, especially for people with disabilities or patients suffering from chronic conditions. About PETRA 2024: PETRA (PErvasive Technologies Related to Assistive Environments) is a premier interdisciplinary conference focusing on computational and engineering approaches to enhance human performance and improve the quality of life. Join us in exploring the latest advancements in assistive technologies across various settings. More info: http://www.petrae.org/index.html Looking forward to an enriching exchange of ideas and knowledge at PETRA 2024! Banner1-2024.png Banner1-2024.png 1/1 PREVIOUS NEXT

< BACK Call for Workshop Papers: AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact May 16, 2025 A joint workshop by iPROLEPSIS and AI-PROGNOSIS at IEEE HealthCom 2025 in Abu Dhabi, focusing on AI-enabled Digital Health Tools for Non-Communicable Diseases The iPROLEPSIS and AI-PROGNOSIS projects are co-organising a workshop titled: “AI-enabled Digital Health Tools for Non-Communicable Diseases: From Concepts to Impact” as part of the IEEE HealthCom 2025 conference , taking place on 21–23 October 2025 in Abu Dhabi, United Arab Emirates. More information: https://healthcom2025.ieee-healthcom.org/program/ai-enabled-digital-health-tools-non-communicable-diseases-concepts-impact We invite authors to submit original research, position papers, or case studies with practical insights. Topics of interest include (but are not limited to): Predictive models for early detection, risk assessment, and prognosis of NCDs Digital biomarkers and wearable sensors for NCDs Machine learning for personalized treatment, disease management, and precision medicine AI in remote care, mHealth, and telemedicine for NCDs Regulatory and ethical considerations in AI-enabled software as medical device Data quality, fairness, and explainability in AI health applications User-centered design in AI-enabled health technology for chronic conditions Translational pathways from research prototypes to scalable digital health solutions The workshop aims to feature 10 selected papers. Important dates: Workshop paper submission July 1, 2025 Acceptance notifications August 15, 2025 Camera Ready papers August 30, 2025 For any questions, please contact: Dr. Vasileios Charisis , Aristotle University of Thessaloniki, Greece – vaschar@auth.gr Dr. Stelios Hadjidimitriou , Aristotle University of Thessaloniki, Greece – shadjidim@ece.auth.gr HealthCom 2025_Call for WS papers_Digital Health Tools for NCDs .pdf Download PDF • 181KB iPROLEPSIS_Call for workshop papers.png iPROLEPSIS_Call for workshop papers.png 1/1 PREVIOUS NEXT